Compare Neurocrine Biosciences Inc (NBIX) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Synopsys, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while Synopsys, Inc. trades at $398.6 (market cap $75.36B). The key difference: Synopsys, Inc. is far larger — about 4.8× Neurocrine Biosciences Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals.
| NBIX | SNPS | |
|---|---|---|
Market Cap | $15.77B | $75.36B |
Sector | Health | Technology |
52-Week High | $185.50 | $534.56 |
52-Week Low | $123.10 | $372.33 |
Enterprise Value | $15.78B | $82.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Synopsys (SNPS) trades at $392.03, down 0.46% on the day, with a bearish technical signal from moving averages but strong fundamental performance including three consecutive quarterly EPS beats. Revenue reached $7.05B in 2025 with an 11.43% net income margin, though valuation ratios like a P/E of 68.42 appear elevated. Recent news highlights its critical role in AI chip design and integration benefits from the Ansys acquisition.
The outlook is supported by Wall Street's bullish consensus with a $541.88 price target, but risks include high valuation sensitivity, competitive pressures in semiconductor software, and macroeconomic headwinds. Earnings growth and execution on raised 2026 guidance are key catalysts for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
